• BS Bioengineering | UC Berkeley 2005
  • PhD Bioengineering | UC San Diego 2011
  • MD | UC San Diego 2013
  • Residency | UC San Diego 2018
  • Clinical Focus | Brain Tumors, Urologic Cancer, Breast Cancer, SRS, General Radiation Oncology

Dr. Tyler Seibert is an Assistant Professor and treats patients at our Encinitas Treatment Center. He oversees a research lab in Center of Precision Radiation Medicine (CPRM) within the UC San Diego Altman Clinical Translational Research Institute (ACTRI) and holds a Joint Appointment with the UC San Diego Department of Bioengineering. He holds a Joint Appointment in the Department of Radiology and is a Faculty-Affiliate in the Department of Bioengineering.

He is a dedicated clinical translational researcher with interests in both novel imaging research and genetics. He is a recipient of a K08 Award from the National Institutes of Health (NIH) and National Institute of Biomedical Imaging and Bioengineering (NIBIB) to explore the utility of whole-body RSI MR imaging in patients with high-risk/metastatic prostate cancer. His research group also uses advanced quantitative imaging tools to measure radiation effects on the brain. In the genomics space, Dr. Seibert heads UC San Diego’s participation in an international prostate cancer genetics consortium (PRACTICAL). The Seibert Lab develops and validates genetic risk models to identify men at risk of developing aggressive prostate cancer and to predict at what age they should undergo screening. He has published many articles in prominent scientific journals, including Radiology, Cancer, and the BMJ. He has presented at numerous national and international conferences and symposia.

In addition to his research, Dr. Seibert is a dedicated physician who treats patients with a wide variety of tumors, including Brain Tumors, Prostate Cancer, and Breast Cancer. He serves on committees for the Radiological Society of North America (RSNA), the American Society for Radiation Oncology (ASTRO), and the UC San Diego campus-wide Academic Senate.